APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Quetiapine Fumarate Sustained Release Tablets

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Quetiapine Fumarate Sustained Release Tablets Market Outlook and Growth Opportunities 2026

Report ID 174030310429 December 2025196 pages

Choose your research edition.

Industry ResearchQuetiapine Fumarate Sustained Release Tablets Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Quetiapine Fumarate Sustained Release Tablets Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Quetiapine Fumarate Sustained Release Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Quetiapine Fumarate Sustained Release Tablets Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Quetiapine Fumarate Sustained Release Tablets Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Quetiapine Fumarate Sustained Release Tablets market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Quetiapine Fumarate Sustained Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Quetiapine Fumarate Sustained Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Quetiapine Fumarate Sustained Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Quetiapine Fumarate Sustained Release Tablets market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Quetiapine Fumarate Sustained Release Tablets market include Dr. Reddy's Laboratories, Lupin Limited, Luye Pharma Limited, PHARMATHEN INVESTMENTS GROUP LIMITED, Seroquel, Torrent Pharmaceuticals, Mylan N.V., Sandoz and Sun Pharmaceutical Industries, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Quetiapine Fumarate Sustained Release Tablets market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Quetiapine Fumarate Sustained Release Tablets and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Quetiapine Fumarate Sustained Release Tablets revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Quetiapine Fumarate Sustained Release Tablets market.

Quetiapine Fumarate Sustained Release Tablets Segment by Company

Dr. Reddy's Laboratories

Lupin Limited

Luye Pharma Limited

PHARMATHEN INVESTMENTS GROUP LIMITED

Seroquel

Torrent Pharmaceuticals

Mylan N.V.

Sandoz

Sun Pharmaceutical Industries

Teva Pharmaceutical Industries

Quetiapine Fumarate Sustained Release Tablets Segment by Type

50mg

200mg

300mg

400mg

Quetiapine Fumarate Sustained Release Tablets Segment by Application

Hospital

Clinic

Others

Quetiapine Fumarate Sustained Release Tablets Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Quetiapine Fumarate Sustained Release Tablets status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Quetiapine Fumarate Sustained Release Tablets key companies, revenue, market share, and recent developments.

3. To split the Quetiapine Fumarate Sustained Release Tablets breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Quetiapine Fumarate Sustained Release Tablets market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Quetiapine Fumarate Sustained Release Tablets significant trends, drivers, influence factors in global and regions.

6. To analyze Quetiapine Fumarate Sustained Release Tablets competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Quetiapine Fumarate Sustained Release Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Quetiapine Fumarate Sustained Release Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Quetiapine Fumarate Sustained Release Tablets.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Quetiapine Fumarate Sustained Release Tablets industry.

Chapter 3: Detailed analysis of Quetiapine Fumarate Sustained Release Tablets company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Quetiapine Fumarate Sustained Release Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Quetiapine Fumarate Sustained Release Tablets in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Quetiapine Fumarate Sustained Release Tablets Industry Trends Table 2. Quetiapine Fumarate Sustained Release Tablets Industry Drivers Table 3. Quetiapine Fumarate Sustained Release Tablets Industry Opportunities and Challenges Table 4. Quetiapine Fumarate Sustained Release Tablets Industry Restraints Table 5. Global Quetiapine Fumarate Sustained Release Tablets Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Quetiapine Fumarate Sustained Release Tablets Revenue Share by Company (2021-2026) Table 7. Global Quetiapine Fumarate Sustained Release Tablets Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Quetiapine Fumarate Sustained Release Tablets Key Company Manufacturing Base & Headquarters Table 9. Global Quetiapine Fumarate Sustained Release Tablets Company, Product Type & Application Table 10. Global Quetiapine Fumarate Sustained Release Tablets Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Quetiapine Fumarate Sustained Release Tablets by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of 50mg Table 15. Significant Companies of 200mg Table 16. Significant Companies of 300mg Table 17. Significant Companies of 400mg Table 18. Global Quetiapine Fumarate Sustained Release Tablets Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Quetiapine Fumarate Sustained Release Tablets Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Quetiapine Fumarate Sustained Release Tablets Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type (2021-2026) Table 22. Global Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospital Table 24. Significant Companies of Clinic Table 25. Significant Companies of Others Table 26. Global Quetiapine Fumarate Sustained Release Tablets Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Quetiapine Fumarate Sustained Release Tablets Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Quetiapine Fumarate Sustained Release Tablets Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application (2021-2026) Table 30. Global Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application (2027-2032) Table 31. Global Quetiapine Fumarate Sustained Release Tablets Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Quetiapine Fumarate Sustained Release Tablets Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Region (2021-2026) Table 34. Global Quetiapine Fumarate Sustained Release Tablets Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Region (2027-2032) Table 36. Global Quetiapine Fumarate Sustained Release Tablets Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Quetiapine Fumarate Sustained Release Tablets Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Quetiapine Fumarate Sustained Release Tablets Sales Value Market Share by Country (2021-2026) Table 39. Global Quetiapine Fumarate Sustained Release Tablets Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Quetiapine Fumarate Sustained Release Tablets Sales Value Market Share by Country (2027-2032) Table 41. Dr. Reddy's Laboratories Company Information Table 42. Dr. Reddy's Laboratories Business Overview Table 43. Dr. Reddy's Laboratories Quetiapine Fumarate Sustained Release Tablets Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Dr. Reddy's Laboratories Quetiapine Fumarate Sustained Release Tablets Product Portfolio Table 45. Dr. Reddy's Laboratories Recent Development Table 46. Lupin Limited Company Information Table 47. Lupin Limited Business Overview Table 48. Lupin Limited Quetiapine Fumarate Sustained Release Tablets Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Lupin Limited Quetiapine Fumarate Sustained Release Tablets Product Portfolio Table 50. Lupin Limited Recent Development Table 51. Luye Pharma Limited Company Information Table 52. Luye Pharma Limited Business Overview Table 53. Luye Pharma Limited Quetiapine Fumarate Sustained Release Tablets Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Luye Pharma Limited Quetiapine Fumarate Sustained Release Tablets Product Portfolio Table 55. Luye Pharma Limited Recent Development Table 56. PHARMATHEN INVESTMENTS GROUP LIMITED Company Information Table 57. PHARMATHEN INVESTMENTS GROUP LIMITED Business Overview Table 58. PHARMATHEN INVESTMENTS GROUP LIMITED Quetiapine Fumarate Sustained Release Tablets Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. PHARMATHEN INVESTMENTS GROUP LIMITED Quetiapine Fumarate Sustained Release Tablets Product Portfolio Table 60. PHARMATHEN INVESTMENTS GROUP LIMITED Recent Development Table 61. Seroquel Company Information Table 62. Seroquel Business Overview Table 63. Seroquel Quetiapine Fumarate Sustained Release Tablets Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Seroquel Quetiapine Fumarate Sustained Release Tablets Product Portfolio Table 65. Seroquel Recent Development Table 66. Torrent Pharmaceuticals Company Information Table 67. Torrent Pharmaceuticals Business Overview Table 68. Torrent Pharmaceuticals Quetiapine Fumarate Sustained Release Tablets Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Torrent Pharmaceuticals Quetiapine Fumarate Sustained Release Tablets Product Portfolio Table 70. Torrent Pharmaceuticals Recent Development Table 71. Mylan N.V. Company Information Table 72. Mylan N.V. Business Overview Table 73. Mylan N.V. Quetiapine Fumarate Sustained Release Tablets Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Mylan N.V. Quetiapine Fumarate Sustained Release Tablets Product Portfolio Table 75. Mylan N.V. Recent Development Table 76. Sandoz Company Information Table 77. Sandoz Business Overview Table 78. Sandoz Quetiapine Fumarate Sustained Release Tablets Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Sandoz Quetiapine Fumarate Sustained Release Tablets Product Portfolio Table 80. Sandoz Recent Development Table 81. Sun Pharmaceutical Industries Company Information Table 82. Sun Pharmaceutical Industries Business Overview Table 83. Sun Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Sun Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Product Portfolio Table 85. Sun Pharmaceutical Industries Recent Development Table 86. Teva Pharmaceutical Industries Company Information Table 87. Teva Pharmaceutical Industries Business Overview Table 88. Teva Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Teva Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Product Portfolio Table 90. Teva Pharmaceutical Industries Recent Development Table 91. Research Programs/Design for This Report Table 92. Authors List of This Report Table 93. Secondary Sources Table 94. Primary Sources List of Figures Figure 1. Quetiapine Fumarate Sustained Release Tablets Product Image Figure 2. Global Quetiapine Fumarate Sustained Release Tablets Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Quetiapine Fumarate Sustained Release Tablets Market Size (2021-2032) & (US$ Million) Figure 4. Global Quetiapine Fumarate Sustained Release Tablets Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. 50mg Image Figure 8. 200mg Image Figure 9. 300mg Image Figure 10. 400mg Image Figure 11. Global Quetiapine Fumarate Sustained Release Tablets Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Quetiapine Fumarate Sustained Release Tablets Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type (2021-2032) Figure 14. Hospital Image Figure 15. Clinic Image Figure 16. Others Image Figure 17. Global Quetiapine Fumarate Sustained Release Tablets Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Quetiapine Fumarate Sustained Release Tablets Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application (2021-2032) Figure 20. Global Quetiapine Fumarate Sustained Release Tablets Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Quetiapine Fumarate Sustained Release Tablets Sales Value (2021-2032) & (US$ Million) Figure 23. North America Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Quetiapine Fumarate Sustained Release Tablets Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Quetiapine Fumarate Sustained Release Tablets Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Quetiapine Fumarate Sustained Release Tablets Sales Value (2021-2032) & (US$ Million) Figure 29. South America Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Quetiapine Fumarate Sustained Release Tablets Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • 50mg
  • 200mg
  • 300mg
  • 400mg
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Dr. Reddy's Laboratories
  • Lupin Limited
  • Luye Pharma Limited
  • PHARMATHEN INVESTMENTS GROUP LIMITED
  • Seroquel
  • Torrent Pharmaceuticals
  • Mylan N.V.
  • Sandoz
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical Industries

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Quetiapine Fumarate Sustained Release Tablets Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Quetiapine Fumarate Sustained Release Tablets Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Quetiapine Fumarate Sustained Release Tablets Market Dynamics
  1. 2.1 Quetiapine Fumarate Sustained Release Tablets Industry Trends
  2. 2.2 Quetiapine Fumarate Sustained Release Tablets Industry Drivers
  3. 2.3 Quetiapine Fumarate Sustained Release Tablets Industry Opportunities and Challenges
  4. 2.4 Quetiapine Fumarate Sustained Release Tablets Industry Restraints
3 Quetiapine Fumarate Sustained Release Tablets Market by Company
  1. 3.1 Global Quetiapine Fumarate Sustained Release Tablets Company Revenue Ranking in 2025
  2. 3.2 Global Quetiapine Fumarate Sustained Release Tablets Revenue by Company (2021-2026)
  3. 3.3 Global Quetiapine Fumarate Sustained Release Tablets Company Ranking (2024-2026)
  4. 3.4 Global Quetiapine Fumarate Sustained Release Tablets Company Manufacturing Base and Headquarters
  5. 3.5 Global Quetiapine Fumarate Sustained Release Tablets Company Product Type and Application
  6. 3.6 Global Quetiapine Fumarate Sustained Release Tablets Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Quetiapine Fumarate Sustained Release Tablets Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Quetiapine Fumarate Sustained Release Tablets Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Quetiapine Fumarate Sustained Release Tablets Market by Type
  1. 4.1 Quetiapine Fumarate Sustained Release Tablets Type Introduction
  2. 4.1.1 50mg
  3. 4.1.2 200mg
  4. 4.1.3 300mg
  5. 4.1.4 400mg
  6. 4.2 Global Quetiapine Fumarate Sustained Release Tablets Sales Value by Type
  7. 4.2.1 Global Quetiapine Fumarate Sustained Release Tablets Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Quetiapine Fumarate Sustained Release Tablets Sales Value by Type (2021-2032)
  9. 4.2.3 Global Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type (2021-2032)
5 Quetiapine Fumarate Sustained Release Tablets Market by Application
  1. 5.1 Quetiapine Fumarate Sustained Release Tablets Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Quetiapine Fumarate Sustained Release Tablets Sales Value by Application
  6. 5.2.1 Global Quetiapine Fumarate Sustained Release Tablets Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Quetiapine Fumarate Sustained Release Tablets Sales Value by Application (2021-2032)
  8. 5.2.3 Global Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application (2021-2032)
6 Quetiapine Fumarate Sustained Release Tablets Regional Value Analysis
  1. 6.1 Global Quetiapine Fumarate Sustained Release Tablets Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Quetiapine Fumarate Sustained Release Tablets Sales Value by Region (2021-2032)
  3. 6.2.1 Global Quetiapine Fumarate Sustained Release Tablets Sales Value by Region: 2021-2026
  4. 6.2.2 Global Quetiapine Fumarate Sustained Release Tablets Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Quetiapine Fumarate Sustained Release Tablets Sales Value (2021-2032)
  7. 6.3.2 North America Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Quetiapine Fumarate Sustained Release Tablets Sales Value (2021-2032)
  10. 6.4.2 Europe Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Quetiapine Fumarate Sustained Release Tablets Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Quetiapine Fumarate Sustained Release Tablets Sales Value (2021-2032)
  16. 6.6.2 South America Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Quetiapine Fumarate Sustained Release Tablets Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Country, 2025 VS 2032
7 Quetiapine Fumarate Sustained Release Tablets Country-level Value Analysis
  1. 7.1 Global Quetiapine Fumarate Sustained Release Tablets Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Quetiapine Fumarate Sustained Release Tablets Sales Value by Country (2021-2032)
  3. 7.2.1 Global Quetiapine Fumarate Sustained Release Tablets Sales Value by Country (2021-2026)
  4. 7.2.2 Global Quetiapine Fumarate Sustained Release Tablets Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Quetiapine Fumarate Sustained Release Tablets Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Quetiapine Fumarate Sustained Release Tablets Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Dr. Reddy's Laboratories
  2. 8.1.1 Dr. Reddy's Laboratories Company Information
  3. 8.1.2 Dr. Reddy's Laboratories Business Overview
  4. 8.1.3 Dr. Reddy's Laboratories Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Dr. Reddy's Laboratories Quetiapine Fumarate Sustained Release Tablets Product Portfolio
  6. 8.1.5 Dr. Reddy's Laboratories Recent Developments
  7. 8.2 Lupin Limited
  8. 8.2.1 Lupin Limited Company Information
  9. 8.2.2 Lupin Limited Business Overview
  10. 8.2.3 Lupin Limited Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Lupin Limited Quetiapine Fumarate Sustained Release Tablets Product Portfolio
  12. 8.2.5 Lupin Limited Recent Developments
  13. 8.3 Luye Pharma Limited
  14. 8.3.1 Luye Pharma Limited Company Information
  15. 8.3.2 Luye Pharma Limited Business Overview
  16. 8.3.3 Luye Pharma Limited Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Luye Pharma Limited Quetiapine Fumarate Sustained Release Tablets Product Portfolio
  18. 8.3.5 Luye Pharma Limited Recent Developments
  19. 8.4 PHARMATHEN INVESTMENTS GROUP LIMITED
  20. 8.4.1 PHARMATHEN INVESTMENTS GROUP LIMITED Company Information
  21. 8.4.2 PHARMATHEN INVESTMENTS GROUP LIMITED Business Overview
  22. 8.4.3 PHARMATHEN INVESTMENTS GROUP LIMITED Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2021-2026)
  23. 8.4.4 PHARMATHEN INVESTMENTS GROUP LIMITED Quetiapine Fumarate Sustained Release Tablets Product Portfolio
  24. 8.4.5 PHARMATHEN INVESTMENTS GROUP LIMITED Recent Developments
  25. 8.5 Seroquel
  26. 8.5.1 Seroquel Company Information
  27. 8.5.2 Seroquel Business Overview
  28. 8.5.3 Seroquel Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Seroquel Quetiapine Fumarate Sustained Release Tablets Product Portfolio
  30. 8.5.5 Seroquel Recent Developments
  31. 8.6 Torrent Pharmaceuticals
  32. 8.6.1 Torrent Pharmaceuticals Company Information
  33. 8.6.2 Torrent Pharmaceuticals Business Overview
  34. 8.6.3 Torrent Pharmaceuticals Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Torrent Pharmaceuticals Quetiapine Fumarate Sustained Release Tablets Product Portfolio
  36. 8.6.5 Torrent Pharmaceuticals Recent Developments
  37. 8.7 Mylan N.V.
  38. 8.7.1 Mylan N.V. Company Information
  39. 8.7.2 Mylan N.V. Business Overview
  40. 8.7.3 Mylan N.V. Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Mylan N.V. Quetiapine Fumarate Sustained Release Tablets Product Portfolio
  42. 8.7.5 Mylan N.V. Recent Developments
  43. 8.8 Sandoz
  44. 8.8.1 Sandoz Company Information
  45. 8.8.2 Sandoz Business Overview
  46. 8.8.3 Sandoz Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sandoz Quetiapine Fumarate Sustained Release Tablets Product Portfolio
  48. 8.8.5 Sandoz Recent Developments
  49. 8.9 Sun Pharmaceutical Industries
  50. 8.9.1 Sun Pharmaceutical Industries Company Information
  51. 8.9.2 Sun Pharmaceutical Industries Business Overview
  52. 8.9.3 Sun Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sun Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Product Portfolio
  54. 8.9.5 Sun Pharmaceutical Industries Recent Developments
  55. 8.10 Teva Pharmaceutical Industries
  56. 8.10.1 Teva Pharmaceutical Industries Company Information
  57. 8.10.2 Teva Pharmaceutical Industries Business Overview
  58. 8.10.3 Teva Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Teva Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Product Portfolio
  60. 8.10.5 Teva Pharmaceutical Industries Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst